Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
Holding PSNL?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.28Last Year’s EPS
-0.54Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2019
|% Change Since: -12.37%
|Next Earnings Date:Aug 13, 2019
Earnings Call Sentiment|Positive
The earnings call indicates strong revenue growth and successful capital raising, which are positive signs for Personalis' future. However, the net loss increase and expected revenue decline in the next quarter present challenges. Overall, the positive aspects slightly outweigh the negatives, as the company seems well-positioned for future growth, particularly in the MRD market.Company Guidance
During the third quarter of 2024 earnings call for Personalis (PSNL), executives provided guidance reflecting strong financial performance and strategic advancements. The company reported a 41% year-over-year revenue increase to $25.7 million, driven by a 96% growth in their biopharma business and high demand for their tumor profiling and MRD product, NeXT Personal. Gross margin improved to 34%, up from 19.1% the previous year. Personalis raised $62 million, ending the quarter with $143.7 million in cash, expected to support operations through 2027. They revised their 2024 revenue guidance to $83-$84 million, with anticipated Q4 revenue between $15-$16 million due to a projected decline in Moderna revenue. The company emphasized their focus on MRD, aiming for Medicare reimbursement for two indications by 2025, and highlighted their collaboration with Tempus and biopharma clients as key growth engines.Record Revenue Growth
Personalis achieved revenue of $25.7 million in Q3 2024, marking a 41% increase year-over-year. This growth was primarily driven by a 96% increase in biopharma business revenue, led by strong demand for the tumor profiling product and NeXT Personal MRD product.
Successful Capital Raise
Personalis raised approximately $62 million in Q3 2024 through a combination of investments from Tempus and accessing the ATM, ending the quarter with $143.7 million in cash.
Expansion of MRD Testing
Personalis delivered 945 clinical tests in Q3 2024, a 68% increase from the previous quarter, driven by strong adoption of NeXT Personal in the clinical market.
Gross Margin Improvement
Gross margin expanded to 34% in Q3 2024, up from 19.1% in the same period last year, due to favorable customer mix and increased revenue volume.
---
PSNL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PSNL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $5.58 | $4.32 | -22.58% |
| Aug 07, 2024 | $2.88 | $3.43 | +19.10% |
| May 08, 2024 | $1.56 | $1.65 | +5.77% |
| Feb 28, 2024 | $1.46 | $1.55 | +6.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Personalis Inc (PSNL) report earnings?
Personalis Inc (PSNL) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Personalis Inc (PSNL) earnings time?
Personalis Inc (PSNL) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PSNL EPS forecast?
PSNL EPS forecast for the fiscal quarter 2024 (Q4) is -0.28.
---